Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FRECLOVIR is a generic antiviral medication manufactured by the Vietnamese pharmaceutical company Fremed. It contains acyclovir, a synthetic purine nucleoside analogue that exhibits inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), as well as varicella-zoster virus (VZV). Acyclovir functions as a prodrug; it is selectively converted into acyclovir monophosphate by viral thymidine kinase, and subsequently into acyclovir triphosphate by host cell kinases. Acyclovir triphosphate acts as a competitive inhibitor of viral DNA polymerase and, more importantly, is incorporated into the growing viral DNA chain, where it acts as a potent chain terminator due to the lack of a 3'-hydroxyl group. This mechanism effectively halts viral replication. FRECLOVIR is commercially available in 200 mg and 400 mg tablet formulations for the treatment of various herpetic infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FRECLOVIR.